A new study has sent a clear warning to the millions using popular diabetes and weight-loss drugs: stopping the medication could nearly double your risk of heart attack or stroke, erasing the significant cardiovascular benefits these drugs provide.
What the New Research Found
Recent
research highlights a significant risk for patients who stop taking a popular class of drugs known as GLP-1 receptor agonists. A new study published in 'The Lancet Regional Health Europe' found that people with type 2 diabetes who discontinued these medications had about double the risk of suffering a non-fatal heart attack, a non-fatal stroke, or death from any cause compared to those who continued their treatment. The study tracked over 80,000 patients in Italy and observed that for every 100 people who stopped the drug, approximately four experienced one of these major adverse events each year, compared to just two events per 100 people who stayed on the medication. This finding underscores that the protective heart benefits of these drugs are not permanent and fade quickly once the treatment is no longer active in the body.
The Drugs in Question
The medications at the center of this research are GLP-1 receptor agonists, a class of drugs that has surged in popularity for managing type 2 diabetes and, more recently, for weight loss. This category includes widely recognized brand names such as Ozempic, Wegovy, and Mounjaro (semaglutide and tirzepatide). These drugs work by mimicking a natural hormone that helps regulate blood sugar and appetite. Beyond their effects on glucose and weight, studies have consistently shown they offer powerful cardiovascular protection. The new research, however, reveals that these benefits are conditional on continuous use. The Italian study primarily looked at patients using older GLP-1s like liraglutide and dulaglutide, but experts believe the findings are relevant across the entire drug class.
Why Does Risk Rebound After Stopping?
The cardiovascular protection offered by GLP-1 drugs is an active benefit, not a permanent cure. When a person stops taking them, the mechanisms that lower risk—such as reduced inflammation, improved blood pressure, and better cholesterol levels—also cease. A senior author of a similar study from Washington University, Dr. Ziyad Al-Aly, described this phenomenon as a 'metabolic whiplash'. While the weight regain after stopping is a visible consequence, the invisible reversal of metabolic health markers is what appears to drive the renewed cardiovascular risk. Essentially, the body loses the drug’s support system, and underlying risk factors for heart disease and stroke can quickly return or worsen. Researchers noted that the benefits begin to erode within months. One study found that after two years off the drugs, the risk of heart attack, stroke, and death was up to 22% higher, largely wiping out the protection gained during treatment.
Who Needs to Be Most Careful?
The findings are particularly critical for patients with type 2 diabetes, who were the focus of the recent Lancet study. That study also found the rebound risk was even higher for patients with obesity (a BMI over 30), who saw a 127% increased cardiovascular risk after stopping, compared to a 61% increase for those without obesity. Many patients stop these medications for various reasons, including high cost, bothersome side effects like nausea, or supply shortages. Some may also mistakenly believe the drugs are a shortterm fix rather than a longterm treatment for a chronic condition. Experts caution that these are chronic medications for chronic diseases. The decision to stop should never be taken lightly or without medical supervision, especially for those with preexisting heart disease risk factors.
What Should Patients Do?
The primary message from researchers and doctors is clear: do not stop taking your GLP‑1 medication abruptly or without consulting your healthcare provider. These findings reinforce the idea that drugs like Ozempic and Wegovy should be viewed as long‑term therapies for managing chronic conditions like diabetes and obesity, not as a quick fix. If you are experiencing side effects, struggling with the cost, or considering stopping for any other reason, have a conversation with your doctor first. They may be able to adjust the dosage, manage side effects, or explore alternative treatment plans. For those who must stop, it is crucial to work with a doctor to monitor blood sugar, blood pressure, and cholesterol levels closely and to intensify efforts around diet and exercise to mitigate the rebound in risk.
